|
1
|
Yu H, Diamandis EP, Prestigiacomo AF and
Stamey TA: Ultrasensitive assay of prostate-specific antigen used
for early detection of prostate cancer relapse and estimation of
tumor-doubling time after radical prostatectomy. Clin Chem.
41:430–434. 1995.
|
|
2
|
Blute ML, Bergstralh EJ, Iocca A, Scherer
B and Zincke H: Use of Gleason score, prostate specific antigen,
seminal vesicle and margin status to predict biochemical failure
after radical prostatectomy. J Urol. 165:119–125. 2001.
|
|
3
|
Freedland SJ, Aronson WJ, Terris MK, et
al; SEARCH Database Study Group. Percent of prostate needle biopsy
cores with cancer is significant independent predictor of prostate
specific antigen recurrence following radical prostatectomy:
results from SEARCH database. J Urol. 169:2136–2141. 2003.
|
|
4
|
Gretzer MB, Epstein JI, Pound CR, Walsh PC
and Partin AW: Substratification of stage T1C prostate cancer based
on the probability of biochemical recurrence. Urology.
60:1034–1039. 2002.
|
|
5
|
Epstein JI, Amin M, Boccon-Gibod L, et al:
Prognostic factors and reporting of prostate carcinoma in radical
prostatectomy and pelvic lymphadectomy specimens. Scand J Urol
Nephrol Suppl. 216:34–63. 2005.
|
|
6
|
Tan PH, Cheng L, Srigley JR, et al; ISUP
Prostate Cancer Group. International Society of Urological
Pathology (ISUP) Consensus Conference on Handling and Staging of
Radical Prostatectomy Specimens. Working group 5: surgical margins.
Mod Pathol. 24:48–57. 2011.
|
|
7
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL; ISUP Grading Committee. The 2005 International Society
of Urological Pathology (ISUP) Consensus Conference on Gleason
Grading of Prostatic Carcinoma. Am J Surg Pathol. 29:1228–1242.
2005.
|
|
8
|
Leslie HS, Mary KG and Christian W: TNM
Classification of Malignant Tumors. 7th edition. Wiley-Blackwell;
Oxford: 2009
|
|
9
|
European Association of Urology.
Guidelines on prostate cancer. http://www.uroweb.org/guidelines/online-guidelines/.
Accessed February 1, 2014
|
|
10
|
Yu H, Diamandis EP, Levesque M, et al:
Ectopic production of prostate specific antigen by a breast tumor
metastatic to the ovary. J Clin Lab Anal. 8:251–253. 1994.
|
|
11
|
Monne M, Croce CM, Yu H and Diamandis EP:
Molecular characterization of prostate-specific antigen messenger
RNA expressed in breast tumors. Cancer Res. 54:6344–6347. 1994.
|
|
12
|
Yu H, Diamandis EP, Levesque M, et al:
Expression of the prostate-specific antigen gene by a primary
ovarian carcinoma. Cancer Res. 55:1603–1606. 1995.
|
|
13
|
Yu H and Diamandis EP: Prostate-specific
antigen in milk of lactating women. Clin Chem. 41:54–58. 1995.
|
|
14
|
Levesque M, Hu H, D’Costa M and Diamandis
EP: Prostate-specific antigen expression by various tumors. J Clin
Lab Anal. 9:123–128. 1995.
|
|
15
|
Levesque M, Yu H, D’Costa M, et al:
Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab
Anal. 9:375–379. 1995.
|
|
16
|
Diamandis EP, Yousef GM, Luo LY, et al:
The new human kallikrein gene family: implications in
carcinogenesis. Trends Endocrinol Metab. 11:54–60. 2000.
|
|
17
|
Oesterling JE, Chan DW, Epstein JI, et al:
Prostate specific antigen in the preoperative and postoperative
evaluation of localized prostatic cancer treated with radical
prostatectomy. J Urol. 139:766–772. 1988.
|
|
18
|
Partin AW, Carter HB, Chan DW, et al:
Prostate specific antigen in the staging of localized prostate
cancer: influence of tumor differentiation, tumor volume and benign
hyperplasia. J Urol. 143:747–752. 1990.
|
|
19
|
Wein AJ, Kavoussi LR, Novick AC, Partin
AW, Peters CA and Ramchandani P: Prostate cancer tumor markers.
Campbell-Walsh Urology Tenth Edition Review. McDougal SW: 10th
edition. Elsevier Saunders; Philadelphia, PA: pp. 2748–2762.
2011
|
|
20
|
Stamey TA, Kabalin JN, McNeal JE, et al:
Prostate specific antigen in the diagnosis and treatment of
adenocarcinoma of the prostate. II. Radical prostatectomy treated
patients. J Urol. 141:1076–1083. 1989.
|
|
21
|
Ellis WJ, Vessella RL, Noteboom JL, Lange
PH, Wolfert RL and Rittenhouse HG: Early detection of recurrent
prostate cancer with an ultrasensitive chemiluminescent
prostate-specific antigen assay. Urology. 50:573–579. 1997.
|
|
22
|
Khalifeh A, Kaouk JH, Bhayani S, et al:
Positive surgical margins in robot-assisted partial nephrectomy: a
multi-institutional analysis of oncologic outcomes (leave no tumor
behind). J Urol. 190:1674–1679. 2013.
|
|
23
|
Epstein JI, Pizov G and Walsh PC:
Correlation of pathologic findings with progression after radical
retropubic prostatectomy. Cancer. 71:3582–3593. 1993.
|
|
24
|
Kinoshita H, Kamoto T, Nishiyama H,
Nakamura E, Matsuda T and Ogawa O: Prostate specific antigen nadir
determined using ultra-sensitive prostate specific antigen as a
predictor of biochemical progression after radical prostatectomy in
Japanese males. Int J Urol. 14:930–934. 2007.
|
|
25
|
Schmidt H, DeAngelis G, Eltze E, Gockel I,
Semjonow A and Brandt B: Asynchronous growth of prostate cancer is
reflected by circulating tumor cells delivered from distinct, even
small foci, harboring loss of heterozygosity of the PTEN gene.
Cancer Res. 66:8959–8965. 2006.
|
|
26
|
Arora R, Koch MO, Eble JN, Ulbright TM, Li
L and Cheng L: Heterogeneity of Gleason grade in multifocal
adenocarcinoma of the prostate. Cancer. 100:2362–2366. 2004.
|
